Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$3.64M+46.01%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kang-Huai Wang
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 99
- Beta
- -2.46
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 17.62
Financials
CV has only 10 quarterly periods on file — the charts below show the full history available.
Revenue
$3.64M+46.0%Net Income
$-7.48MEBITDA
$-7.48MFree Cash Flow
$-8.40MEPS (diluted)
$-0.15Shares Outstanding (diluted)
49.94M+22.3%Operating Expenses
$9.45MCash & Debt
$9.08MReturn of Capital
$12.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $13.55M | $-25.32M | $-0.54 |
| 2024 | $11.76M | $-19.90M | $-0.43 |
| 2023 | $9.75M | $-11.30M | $-0.29 |
Valuation
CVhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-68.09%Social Signal Score
Mentions (5)
- Newsglobenewswire.com·8d ago·Neutral
CapsoVision Announces FDA Clearance of AI Highlights for CapsoCam Plus® AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system AI-assisted reading tool designed to aid physician review of small bowel capsule endoscopy studies performed due to suspected bleeding using the CapsoCam Plus® system
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
CapsoVision to Participate in Upcoming Investor Conferences SARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, plan to participate in the following upcoming investor con…
View source ↗ - Newsseekingalpha.com·53d ago·Positive
CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Neutral
CapsoVision Q2 Earnings Call Highlights CapsoVision NASDAQ: CV reported second-quarter revenue growth as sales of its CapsoCam Plus capsule endoscopy system increased, while the company advanced its artificial intelligence software rollout and development programs for colon and upper gastrointestinal applications.
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
CapsoVision Reports Second Quarter 2026 Financial Results SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided a business update for its second quarter ended June 30, 2026.
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.15 per share
Typical surprise -18.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.15 vs $-0.13miss
- Thu, May 14$-0.15 vs $-0.13miss
- Thu, Mar 26$-0.16 vs $-0.17beat
- Thu, Nov 13$-0.17 vs $-0.14miss
- Thu, Aug 14$-2.02 vs $-0.11miss
- Fri, May 9$-1.31 vs $-0.11miss
Estimates and results for CV via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CV officers and directors.
- Bought
- $21.0m
- Sold
- $9k
8 trades
1 trade
- Harari Eliyahou Et Albought
- Harari Eliyahou Et Albought
- Shen Ching Hangbought
- Shen Ching Hangbought
- Harari Eliyahou Et Albought
- Harari Eliyahou Et Albought
- Harari Eliyahou Et Albought
- Imperial Joanne Carolsold
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CV.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.